2025 AHA Bradycardia Algorithm
The 2025 AHA bradycardia algorithm prioritizes immediate identification of symptomatic bradycardia (typically HR <50/min), simultaneous treatment of reversible causes, and escalating pharmacologic or electrical interventions based on clinical response, with atropine as first-line medication followed by transcutaneous pacing or vasoactive agents if refractory. 1
Initial Assessment and Recognition
The 2025 guidelines define bradycardia as a heart rate typically less than 50/min (not the traditional 60/min), reflecting modern population-based evidence 1. The critical first step is determining whether the bradycardia is:
- Symptomatic: Presenting with dizziness, altered mental status, chest pain, acute heart failure, hypotension, or syncope due to decreased cardiac output
- Causing hemodynamic instability: Signs of shock or poor perfusion requiring immediate intervention
Assess appropriateness for the clinical condition - bradycardia may be physiologically normal in athletes, healthy adults, or during sleep 1.
Simultaneous Dual Approach
1. Identify and Treat Reversible Causes
This is critical and must occur alongside stabilization measures 1. Bradycardia may be impossible to resolve without addressing underlying etiologies:
- Myocardial ischemia - most urgent reversible cause
- Hypoxemia - strongly associated with pacing failure and mortality 1
- Electrolyte abnormalities (particularly hyperkalemia)
- Hypothermia
- Medications/toxins (beta-blockers, calcium channel blockers, digoxin)
- Increased vagal tone
- Metabolic derangements (hypothyroidism, acidosis)
- Infections
2. Pharmacologic and Electrical Interventions
Treatment Algorithm
First-Line: Atropine
Atropine is the initial medication of choice for symptomatic bradycardia based on observational evidence showing effectiveness 1. The evidence shows:
- Improved survival to hospital admission in out-of-hospital cardiac arrest with nonshockable rhythms when combined with epinephrine 1
- Less clear benefit in in-hospital cardiac arrest 1
Second-Line: Multiple Reasonable Options
If atropine is ineffective, clinicians have several equivalent alternatives - the choice depends on available resources and clinician experience 1:
Option A: Transcutaneous Pacing
- Noninvasive and rapid - can be performed immediately at bedside
- Serves as bridge to transvenous pacing
- Major caveat: Often painful in conscious patients, requiring sedation 1
- Critical challenge: Difficulty achieving and maintaining true electrical and mechanical capture 1
- Evidence shows no survival benefit over standard care in systematic reviews, though subgroup analysis suggests possible benefit in symptomatic (not arrest) bradycardia 1
Option B: Epinephrine
- IV infusion or "push-dose" administration gaining popularity 1
- Limited direct evidence for bradycardia specifically
- Major caveat: Requires careful attention to correct dosing - medication errors and adverse hemodynamic effects reported 1
Option C: Dopamine Infusion
- Can increase heart rate effectively 1
- Randomized feasibility study showed no difference in survival compared to transcutaneous pacing in patients failing atropine 1
Severe Shock Without IV/IO Access
If no vascular access is available in severe symptomatic bradycardia causing shock, initiate immediate transcutaneous pacing while simultaneously obtaining access 1. This represents the one scenario where pacing precedes medication attempts.
Refractory Cases
When medications fail and shock persists, transvenous pacing can improve heart rate and symptoms until definitive treatment (correction of underlying cause or permanent pacemaker placement) 1. Be aware of significant complication rates including bloodstream infections and pneumothorax 1.
Critical Pitfalls to Avoid
False electrical capture: The 2025 guidelines emphasize persistent challenges in distinguishing true capture from artifact 1. Confirm capture with pulse palpation, hemodynamic monitoring, pulse oximetry, continuous ETCO₂, or ultrasound.
Ignoring hypoxia: Hypoxia is specifically identified as a factor associated with pacing failure and increased mortality 1. Address oxygenation immediately.
Push-dose vasopressor errors: If using push-dose epinephrine, extreme caution with dosing is essential given reported medication errors 1.
Treating the number, not the patient: Bradycardia may be physiologically appropriate - evaluate within clinical context 1.
Key Algorithmic Decision Points
The 2025 algorithm follows this sequence:
- Assess if bradycardia is symptomatic and causing hemodynamic compromise
- Simultaneously identify and treat reversible causes
- Administer atropine as first-line pharmacotherapy
- If atropine fails → Choose transcutaneous pacing, epinephrine, or dopamine based on available resources
- If severe shock without access → Immediate transcutaneous pacing while obtaining access
- If refractory → Consider transvenous pacing as bridge to definitive therapy